We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.

Delisted

NAVB was delisted on the 5th of October, 2023.

24 hedge funds and large institutions have $226K invested in Navidea Biopharmaceuticals Inc. in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

63% more capital invested

Capital invested by funds: $139K → $226K (+$87.3K)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 2324 (+1)

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
6
Reduced
2
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CSS
26
Cubist Systematic Strategies
Connecticut
-$920 -10,003 Closed
Northwestern Mutual Wealth Management
27
Northwestern Mutual Wealth Management
Wisconsin
-$10 -110 Closed

NAVB Hedge Fund Activity: Q3 2023 in Review

24 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q3 2023, worth a combined $226K — up 63% from $139K a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new NAVB positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $30.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $11.6K sold.

  • 24 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q3 2023, up from 23 in Q2 2023.
  • Funds reported $226K of Navidea Biopharmaceuticals Inc. stock for Q3 2023, up 63% quarter-over-quarter.
  • 4 funds opened new Navidea Biopharmaceuticals Inc. positions in Q3 2023 and 3 closed out, a net change of +1 holder.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q3 2023 was Virtu Financial, an estimated $30.9K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q3 2023 was Susquehanna International Group, an estimated $11.6K sold.

Based on aggregated 13F filings for Q3 2023.